Sera from both human cytomegalovirus (HCMV)-seropositive adults and infants with congenital HCMV infection recognized two major HCMV glycoprotein complexes. However, proliferative responses of peripheral blood mononuclear cells to these complexes varied among seropositive adults and were not detected in any of the infants. Thus, these glycoproteins alone may not be sufficient to develop a subviral HCMV vaccine.
Human cytomegalovirus (HCMV), like other members of the herpesvirus family, is a relatively common human pathogen and has the ability to produce primary infection ranging from subclinical, asymptomatic illness to rapidly progressive systemic disease with significant morbidity and mortality (13, 16, 31) . The most serious manifestations of HCMV occur in association with immunodeficiency states, including transient, generalized immunodeficiency in patients with HCMV mononucleosis (28, 29) , in an HCMV-specific cellmediated immune defect in infants with congenital HCMV infection (10, 11) , in immunosuppressed patients such as organ and bone marrow transplant recipients (21) , and in patients with acquired immunodeficiency syndrome (17, 25) . To develop an effective subunit HCMV vaccine, it is essential to know which protein(s) can induce protective immune responses in humans.
Because the glycoproteins of HCMV are not only present in the envelopes of virions but are also highly expressed on the surfaces of infected cells involved in productive viral infection (5, 20) , they are likely to be accessible to the immune system. We have previously described two families of HCMV envelope glycoprotein complexes which are biochemically and immunologically distinct (14) . One family of complexes, which we have designated gc-I for purposes of discussion, contains glycoproteins of 130,000, 93,000, and 50,000 to 52,000 daltons, associated by disulfide bonds, which are immunoprecipitated by several monoclonal antibodies (McAbs) and thus appear to be immunologically related. These complexes apparently contain the glycoprotein which was first classified gA by Pereira et al. (20) (4, 14, 22, 23) . However, ongoing HCMV replication after primary infection and symptomatic reactivation of the latent genome is associated with lack of cellular immunity, whether or not antibody is present (2, 8, 18, 27) . Therefore, it seems apparent that HCMV-specific cellular immunity plays a significant role in recovery from HCMV infection. In this report, we present the results of human humoral and cellular immune responses to these two major HCMV glycoprotein complexes in normal adults and in infants with congenital HCMV infection.
HCMV whole viral antigen was obtained as heat-inactivated sucrose-gradient-purified virus pelleted from the supernatant of Towne HCMV-infected fibroblasts. Glycoprotein complexes gc-I and gc-II were purified from detergent extracts of Towne HCMV virions by anion-exchange highpressure liquid chromatography, as previously described (14) . Although ion-exchange high-pressure liquid chromatography provided significant purification of the glycoprotein complexes obtained from either virus-infected cells or purified virus, there was still 5 to 10% cross-contamination between peaks containing gc-I and gc-II, on the basis of immunoprecipitation results (14) . Therefore, before being used to study both adult HCMV-seropositive donors tested, all responded to whole HCMV antigen, but a broad spectrum of lymphocyte proliferative responses to the glycoprotein complexes was observed. Both complexes stimulated high responses in two individuals (Al and A4), intermediate or low responses in five individuals (A2, A3, AS, A6, and A7), and no responses in two individuals (A8 and A9) at 0.1 p,g of glycoprotein per well. This pattern of lymphocyte response was consistent within each individual when tests were performed 6 months apart (data not shown). To confirm that this pattern was true for other antigen concentrations, glycoprotein complexes at a range of 0.4 ng to 1 ,ug per well were tested. Representative results of such experiments are shown (Fig. 1) . Donor A8 did not respond to either glycoprotein complex at any of the concentrations tested. Donor A4 responded to gc-I and gc-II better than did donors A3 and A6 at all concentrations of antigen tested, although peripheral blood mononuclear cells (PBMC) isolated from the three donors responded equally well to whole HCMV antigen. We cannot entirely exclude the possibility that subjects A8 and A9 may have only conformation-dependent T cells reactive with these glycoproteins. It has recently been demonstrated that some T cells recognize conformational determinants on the three-dimensional structure of the native hemagglutinin molecules of (Fig. 2A) . Sera from all seropositive control donors also immunoprecipitated 5 to 12% of the counts per minute in gc-II complexes, and negative sera precipitated 1% or less of the counts per minute in gc-II (data not shown). gc-II complexes were also examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis after reduction. Again, the number and molecular weights of the glycoproteins immunoprecipitated by the human immune sera were very similar to those immunoprecipitated by the gc-II-specific McAb 9E10 (Fig. 2B) . These results suggest that gc-II might be more immunogenic in humans than in mice, based on the fact that murine McAbs against gc-I have been generated in several laboratories (14, (22) (23) (24) , whereas only a single McAb recognizing gc-II has been reported to date (14) . Sera from infants with congenital HCMV infection showed the same immunoprecipitation patterns as sera from normal seropositive adults. These data suggest that the cell-mediated immune defect in infants with congenital HCMV infection does not affect the antibody response to the most abundant envelope glycoproteins of HCMV.
Sera from donors Al, A6, A9, All, and I4 were tested for reactivity to HCMV antigen, gc-I, and gc-II in an enzymelinked immunosorbent assay (Fig. 3) . Again, sera from all seropositive donors recognized both gc-I and gc-II, whereas serum from the seronegative donor All did not react to either HCMV glycoprotein complex. The results shown in Table 1 and Fig. 3 demonstrate that there is no correlation between antibody and lymphocyte proliferative responses to these HCMV glycoproteins in humans. For example, mononuclear cells from donor A9 did not proliferate in response to either gc-I or gc-II (Table 1) whereas serum from the same donor did react with both glycoprotein complexes. Mononuclear cells of donor Al responded to gc-I and gc-II to a greater extent than did cells from any other donor tested, yet the level of antibody against gc-I and gc-II in the serum of donor Al was not higher than that of other donors (i.e., A6 and A9). Sera from infants with congenital HCMV infection reacted with both glycoprotein complexes, but their PBMC did not respond to either glycoprotein in a proliferation assay. The lack of correlation between B-and T-cell responses to HCMV observed in both adults and infants with congenital HCMV infection has also been demonstrated for other viruses (1, 3, 30, 32) . For example, the response of B cells to influenza virus is primarily due to hemagglutinin (15, 30, 32) , whereas both external and internal viral proteins play significant roles in T-cell recognition (3, 30, 32) . For varicella-zoster virus, there is usually an association between antibody responses and lymphocyte proliferation with purified varicella-zoster virus proteins, but discrepancies in the detection of antibody and lymphocyte proliferation in response to the subunit antigens were observed in some individuals (1) .
We believe this is the first report which investigates both human T-and B-cell responses to HCMV envelope glycoproteins. Previously, several laboratories have reported murine McAbs reactive with HCMV glycoprotein complexes identical to gc-I (4, 6, 14, 20, 22, 23) 4 ,ug/ml. Sera from indicated donors at 10-fold dilutions were added to each well and incubated at 25°C for 2 h. After being washed three times with phosphate-buffered saline-Tween, peroxidase-labeled goat anti-human immunoglobulin G (1:2,000; Cooper Biomedical, Inc., West Chester, Pa.) was added. The plates were incubated for another 2 h and were washed. Orthophenylene diamine was then added as the substrate for peroxidase, and the color developed was read in a spectrophotometer at 490 nm. volvement in cellular immune responses, we found no correlation between cellular and humoral responses. Moreover, PBMC from some individuals do not respond to either glycoprotein complex, despite significant proliferative responses to whole HCMV antigen. Therefore, it appears that HCMV proteins other than these envelope glycoproteins are important in stimulating T-cell proliferative responses; one of these has been reported to be a 64,000-dalton matrix protein (7) . Although HCMV envelope glycoproteins appear to consistently induce B-cell responses (9, 12, 20, 22 ; this study), the lack of universal helper T-cell responses to these glycoproteins indicates that a subviral HCMV vaccine composed of these glycoproteins alone may not be sufficient to induce protective immunity. 
